Literature DB >> 15010028

Treatment of Gastroparesis.

Daniel C. Buckles1, Richard W. McCallum.   

Abstract

Gastroparesis is a condition of impaired gastric motility that can be chronic and result in decreased quality of life and complete disability. Once the diagnosis of gastroparesis is established, the clinician's attention should immediately focus on restoring nutritional status, providing symptomatic relief from nausea and vomiting, and improving gastric motility. Combination therapy is the rule rather than the exception, and most patients require multiple prokinetic and antiemetic modalities for adequate symptom relief. Currently available medications are often inadequate to achieve therapeutic goals, and newer modalities, such as gastric electrical stimulation, which has been shown to decrease symptoms and improve quality of life, should be employed at a low threshold. Several novel therapeutic options are under investigation and may also become part of the routine treatment of gastroparesis.

Entities:  

Year:  2004        PMID: 15010028     DOI: 10.1007/s11938-004-0035-z

Source DB:  PubMed          Journal:  Curr Treat Options Gastroenterol        ISSN: 1092-8472


  28 in total

Review 1.  GM-611 (Chugai Pharmaceutical).

Authors:  T L Peeters
Journal:  Curr Opin Investig Drugs       Date:  2001-04

2.  Botulinum toxin for the treatment of gastroparesis: a preliminary report.

Authors:  Brian E Lacy; Estephan N Zayat; Michael D Crowell; Marvin M Schuster
Journal:  Am J Gastroenterol       Date:  2002-06       Impact factor: 10.864

3.  Subcutaneous metoclopramide in the treatment of symptomatic gastroparesis: clinical efficacy and pharmacokinetics.

Authors:  R W McCallum; G Valenzuela; S Polepalle; D Spyker
Journal:  J Pharmacol Exp Ther       Date:  1991-07-01       Impact factor: 4.030

4.  The effect of chronic oral domperidone therapy on gastrointestinal symptoms, gastric emptying, and quality of life in patients with gastroparesis.

Authors:  I Soykan; I Sarosiek; R W McCallum
Journal:  Am J Gastroenterol       Date:  1997-06       Impact factor: 10.864

5.  Assessment of gastric emptying using a low fat meal: establishment of international control values.

Authors:  G Tougas; E Y Eaker; T L Abell; H Abrahamsson; M Boivin; J Chen; M P Hocking; E M Quigley; K L Koch; A Z Tokayer; V Stanghellini; Y Chen; J D Huizinga; J Rydén; I Bourgeois; R W McCallum
Journal:  Am J Gastroenterol       Date:  2000-06       Impact factor: 10.864

6.  Pyloric injection of botulinum toxin for treatment of diabetic gastroparesis.

Authors:  Dina Ezzeddine; Rajkamal Jit; Neil Katz; Narasimh Gopalswamy; Manoop S Bhutani
Journal:  Gastrointest Endosc       Date:  2002-06       Impact factor: 9.427

7.  Demography, clinical characteristics, psychological and abuse profiles, treatment, and long-term follow-up of patients with gastroparesis.

Authors:  I Soykan; B Sivri; I Sarosiek; B Kiernan; R W McCallum
Journal:  Dig Dis Sci       Date:  1998-11       Impact factor: 3.199

8.  Long-term outcome after gastrectomy for intractable diabetic gastroparesis.

Authors:  P J Watkins; M S Buxton-Thomas; E R Howard
Journal:  Diabet Med       Date:  2003-01       Impact factor: 4.359

9.  Progesterone and estrogen are potential mediators of gastric slow-wave dysrhythmias in nausea of pregnancy.

Authors:  J W Walsh; W L Hasler; C E Nugent; C Owyang
Journal:  Am J Physiol       Date:  1996-03

10.  Domperidone in the management of symptoms of diabetic gastroparesis: efficacy, tolerability, and quality-of-life outcomes in a multicenter controlled trial. DOM-USA-5 Study Group.

Authors:  D Silvers; M Kipnes; V Broadstone; D Patterson; E M Quigley; R McCallum; N K Leidy; C Farup; Y Liu; A Joslyn
Journal:  Clin Ther       Date:  1998 May-Jun       Impact factor: 3.393

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.